A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

被引:0
作者
E Senkus-Konefka
R Dziadziuszko
E Bednaruk-Młyński
A Pliszka
J Kubrak
A Lewandowska
K Małachowski
M Wierzchowski
M Matecka-Nowak
J Jassem
机构
[1] Medical University of Gdańsk,Department of Oncology and Radiotherapy
[2] Pomeranian Medical Academy,undefined
[3] Strzałowska 22,undefined
[4] Oncology Center,undefined
[5] Dr Izabeli Romanowskiej 2,undefined
[6] Lower Silesian Oncology Center,undefined
[7] Hirszfelda 2,undefined
[8] The Maria Skłodowska-Curie Memorial Cancer Center & Institute of Oncology,undefined
[9] WK Roentgena 5,undefined
[10] Greatpoland Cancer Centre,undefined
来源
British Journal of Cancer | 2005年 / 92卷
关键词
non-small-cell lung cancer; radiotherapy; palliative treatment;
D O I
暂无
中图分类号
学科分类号
摘要
A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5 fractions (fr)/5 days (arm A) or 16 Gy/2 fr/day 1 and 8 (arm B). There were 90 men and 10 women aged 47–81 years (mean 66), performance status 1–4 (median 2). The major clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects were assessed using patient's chart, doctor's scoring of symptomatic change and chest X-ray. Study end points included degree and duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination. Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC.
引用
收藏
页码:1038 / 1045
页数:7
相关论文
共 50 条
[21]   A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer [J].
Francesco Grossi ;
Filippo de Marinis ;
Vittorio Gebbia ;
Ferdinando Riccardi ;
Orazio Caffo ;
Teresa Gamucci ;
Francesco Ferraù ;
Mario Nardi ;
Luca Moscetti ;
Luca Boni ;
Davide Dondi ;
Enzo Galligioni .
Cancer Chemotherapy and Pharmacology, 2012, 69 :369-375
[22]   A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial [J].
Feng, QF ;
Wang, M ;
Wang, LJ ;
Yang, ZY ;
Zhang, YG ;
Zhang, DW ;
Yin, WB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04) :925-929
[23]   Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience [J].
Bassanelli, M. ;
Giannarelli, D. ;
Ricciuti, B. ;
Magri, V. ;
Cecere, F. L. ;
Roberto, M. ;
Giacinti, S. ;
Barucca, V. ;
Cassese, R. ;
De Giglio, A. ;
Scagnoli, S. ;
Milella, M. ;
Santarelli, M. ;
Bengala, C. ;
Ruggeri, E. M. ;
Marchetti, P. ;
Cognetti, F. ;
Gelibter, A. ;
Cortesi, E. ;
Chiari, R. ;
Ceribelli, A. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S611-S611
[24]   Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer [J].
Bernstein, ED ;
Herbert, SM ;
Hanna, NH .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (03) :291-301
[25]   Neurological examination and brain computed tomography in the initial staging of non-small-cell lung cancer (NSCLC): a prospective study. [J].
Brichet, A ;
Stach, B ;
Dubois, F ;
Pruvo, JP ;
Duhamel, A ;
Lafitte, JJ .
REVUE DES MALADIES RESPIRATOIRES, 1999, 16 (03) :361-368
[26]   Symptom control and quality of life in people with lung cancer: A randomised trial of two palliative radiotherapy fractionation schedules [J].
Erridge, SC ;
Gaze, MN ;
Price, A ;
Kelly, CG ;
Kerr, GR ;
Cull, A ;
MacDougall, RH ;
Howard, GCW ;
Cowie, VJ ;
Gregor, A .
CLINICAL ONCOLOGY, 2005, 17 (01) :61-67
[27]   Combing Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small-cell Lung Cancer [J].
Zou, Y. ;
Chen, Y. ;
Zhou, X. ;
Gong, Y. ;
Xu, Y. ;
Zou, B. ;
Peng, F. ;
Huang, M. ;
Lu, Y. ;
Liu, Y. .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S625-S625
[28]   Au Nanoclusters Embedded in Polydopamine for Photothermal Radiotherapy on Non-Small-Cell Lung Cancer [J].
Hu, Ping ;
Tian, Xiufen ;
Sun, Zhiyu ;
Yu, Xiaojun ;
Wei, Xuguo ;
Jiang, Hechun ;
Wang, Xiali ;
Yang, Dawei ;
Jiang, Xiaohong .
ACS APPLIED NANO MATERIALS, 2024, 7 (16) :19724-19736
[29]   Outcomes of accelerated hypofractionated radiotherapy in stage I non-small-cell lung cancer [J].
Yung, T. ;
Giuliani, M. E. ;
Le, L. W. ;
Sun, A. ;
Cho, B. C. J. ;
Bezjak, A. ;
Brade, A. ;
Hope, A. J. .
CURRENT ONCOLOGY, 2012, 19 (04) :E264-E269
[30]   Optimal radiotherapy for non-small-cell lung cancer: Current progress and future challenges [J].
Ishikura S. .
General Thoracic and Cardiovascular Surgery, 2012, 60 (3) :127-131